文献速递炎症性肠病消化道肿瘤与早癌

生物制剂对晚期炎症性肠病相关肠道癌症风险的影响:一项全国性研究

Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study.
PubMed 文献 · Am J Gastroenterol · 2022-12-14

该全国性多中心研究纳入1983至2020年确诊的1042例炎症性肠病相关异型增生或癌症患者(214例克罗恩病、828例溃疡性结肠炎),比较生物制剂、5-氨基水杨酸和免疫调节剂使用与癌症分期的关系。溃疡性结肠炎患者中晚期癌症与较少使用生物制剂显著相关,生物制剂使用与晚期疾病风险降低显著相关(比值比=0.111,95%CI 0.034-0.356,P<0.001);克罗恩病患者中无药物与癌症分期显著相关。

要点

  • 溃疡性结肠炎患者中,晚期癌症者生物制剂使用比例显著低于早期癌症者(2.0% vs 7.7%,P<0.001)。
  • 常规监测确诊的溃疡性结肠炎患者中,使用生物制剂者晚期癌症发生率低于未使用者(9.1% vs 24.5%,P=0.043)。
  • 多因素分析显示溃疡性结肠炎患者使用生物制剂与晚期疾病风险降低显著相关(比值比=0.111,95%CI 0.034-0.356,P<0.001)。

核心结论

  • 在溃疡性结肠炎患者中,使用生物制剂与晚期炎症性肠病相关癌症风险降低相关;在克罗恩病患者中未观察到该关联。
  • 溃疡性结肠炎与克罗恩病的癌症进展机制可能不同,需进一步研究。

研究设计与样本

  • 全国性多中心数据集研究,纳入1983年至2020年确诊为炎症性肠病相关异型增生或癌症的克罗恩病和溃疡性结肠炎患者医疗记录。
  • 共纳入1042例患者,其中克罗恩病214例、溃疡性结肠炎828例。
  • 治疗药物分为生物制剂、5-氨基水杨酸和免疫调节剂3类,按所用药物比较克罗恩病和溃疡性结肠炎患者的病理癌症分期。

主要发现

  • 克罗恩病患者中,无药物与癌症分期显著相关。
  • 溃疡性结肠炎患者中,晚期癌症与较少使用生物制剂显著相关(早期阶段7.7% vs 晚期阶段2.0%,P<0.001),亦与较少使用5-氨基水杨酸和免疫调节剂相关。
  • 常规监测确诊的患者中,生物制剂使用与晚期癌症发生率降低相关(未使用生物制剂24.5% vs 使用生物制剂9.1%,P=0.043),其他药物无此关联。
  • 多因素分析显示,生物制剂使用与晚期疾病风险降低显著相关(比值比=0.111,95%CI 0.034-0.356,P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The aim of this study was to evaluate the effect of biologics on the risk of advanced-stage inflammatory bowel disease (IBD)-associated intestinal cancer from a nationwide multicenter data set. METHODS: The medical records of patients with Crohn's disease (CD) and ulcerative colitis (UC) diagnosed with IBD-associated intestinal neoplasia (dysplasia or cancer) from 1983 to 2020 were included in this study. Therapeutic agents were classified into 3 types: biologics, 5-aminosalicylic acid, and immunomodulators. The pathological cancer stage was compared based on the drug used in both patients with CD and UC. RESULTS: In total, 1,042 patients (214 CD and 828 UC patients) were included. None of the drugs were significantly associated with cancer stage in the patients with CD. In the patients with UC, an advanced cancer stage was significantly associated with less use of biologics (early stage: 7.7% vs advanced stage: 2.0%, P < 0.001), 5-aminosalicylic acid, and immunomodulators. Biologic use was associated with a lower incidence of advanced-stage cancer in patients diagnosed by regular surveillance (biologics [-] 24.5% vs [+] 9.1%, P = 0.043), but this was not the case for the other drugs. Multivariate analysis showed that biologic use was significantly associated with a lower risk of advanced-stage disease (odds ratio = 0.111 [95% confidence interval, 0.034-0.356], P < 0.001). DISCUSSION: Biologic use was associated with a lower risk of advanced IBD-associated cancer in patients with UC but not with CD. The mechanism of cancer progression between UC and CD may be different and needs to be further investigated.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Seishima R, Okabayashi K, Ikeuchi H, et al. Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study. Am J Gastroenterol. 2022. PMID: 36622356. doi:10.14309/ajg.0000000000002149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。